Primary Care POC Diagnostics Global Market to Observe Highest Growth of $22.19 billion with an Excellent CAGR of 7.8% by 2028 | Quidel Corporation, Sysmex Corporation, Nipro Corporation, OraSure Technologies, DiaSorin SpA

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Primary Care POC Diagnostics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $22.19 billion In 2028 At A CAGR Of 7.8% :

The primary care POC diagnostics market size has grown strongly in recent years. It will grow from $15.32 billion in 2023 to $16.46 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to the increasing prevalence of chronic diseases, shift towards personalized medicine, growing healthcare expenditure, rise in supportive regulatory frameworks and expedited approval processes, and growing emphasis on early disease detection and prevention strategies.

The primary care POC diagnostics market size is expected to see strong growth in the next few years. It will grow to $22.19 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to the emergence of infectious disease outbreaks, expanding applications in non-communicable diseases, increasing adoption in home healthcare settings, growth in precision medicine initiatives, rising healthcare infrastructure investments, increasing disease burden, and growing awareness of the importance of early disease detection. Major trends in the forecast period include the integration of artificial intelligence (AI) and machine learning algorithms, advancements in molecular diagnostics technologies, miniaturization and portability of POC diagnostic devices, integration of smart devices, and usage of multiplexing and panel testing in POC diagnostics.

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=15642&type=smp

Primary Care POC Diagnostics Market Major Segments
The primary care poc diagnostics market covered in this report is segmented -
1) By Product: Glucose Monitoring, Cardiometabolic Testing Products, Infectious Disease Testing Products, Coagulation Testing Products, Pregnancy And Fertility Testing Products, Tumor Or Cancer Marker Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drug-Of-Abuse (DOA) Testing Products, Other Products
2) By Prescription: Prescription Based, Over-The-Counter (OTC) Testing
3) By End-Use: Hospitals, Diagnostic Centers, Research Laboratories, Home-Care Settings, Other End-Uses

Key Driver - Rising Occurrences Of Food Diseases

The rise in the prevalence of infectious diseases is expected to propel the growth of the primary care POC diagnostics market going forward. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. These diseases spread from one person to another directly or indirectly through contact with contaminated surfaces, air, water, or vectors such as insects. The prevalence of infectious diseases is due to poor environmental conditions, urbanization, antimicrobial resistance, and inadequate vaccination coverage. Primary care POC diagnostics are integral tools for combating the prevalence of infectious diseases by facilitating early detection, timely treatment, and effective disease control measures in diverse healthcare settings. For instance, in October 2023, according to a report published by the UK Health Security Agency, a UK-based government agency responsible for overseeing and managing public health security, the number of HIV diagnoses in England rose by 22% from 3,118 in 2021 to 3,805 in 2022. Furthermore, in November 2023, according to the World Health Organization (WHO), a Switzerland-based specialized agency of the United Nations responsible for international public health, around 10.6 million cases of tuberculosis (TB) occurred globally in 2022, affecting 5.8 million men, 3.5 million women, and 1.3 million children. Therefore, the rise in the prevalence of infectious diseases is driving the primary care POC diagnostics market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=15642&type=smp

Prominent Trend - Advancements In Portable Point-Of-Care RT-PCR Solutions Help Enhancing Infectious Disease Diagnosis At The Point Of Care

Major companies operating in the primary care POC diagnostics market are focusing on technologically advanced solutions, such as portable point-of-care RT-PCR solutions, to maximize their revenue in the market. Portable point-of-care (POC) RT-PCR solutions are compact, mobile devices designed to perform real-time reverse transcription polymerase chain reaction (RT-PCR) tests outside traditional laboratory settings. For instance, in October 2022, Genes2Me Pvt. Ltd., an India-based manufacturer of molecular diagnostic solutions, launched the Rapi-Q Point of Care RT PCR solution for diseases such as HPV and tuberculosis. This solution has an eight-well block design with four fluorescent channels, is claimed to be easy to use, and can provide faster results in less than 45 minutes. The Rapi-Q system is portable and lightweight, making it suitable for hospitals, blood banks, health clinics, research laboratories, and airports. The solution offers high sensitivity, accuracy, and performance in detecting various diseases and is compatible with over 50 lyophilized, room-temperature disease detection kits.

Primary Care POC Diagnostics Market Players
Major companies operating in the primary care POC diagnostics market are Hoffmann-La Roche Ltd, Abbott Laboratories, Siemens Healthineers AG, Becton, Dickinson And Company, bioMerieux SA, Quidel Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Nova Biomedical Corporation, Randox Laboratories Ltd, Ortho Clinical Diagnostics, Nipro Corporation, OraSure Technologies, Meridian Bioscience Inc, DiaSorin SpA, Sekisui Diagnostics LLC, EKF Diagnostics Holdings plc, Trinity Biotech plc, Fujirebio Diagnostics Inc., Immunodiagnostic Systems Holdings PLC, Quotient Limited, AccuBioTech Co. Ltd., bioMedomics Inc.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/primary-care-poc-diagnostics-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the primary care POC diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary care POC diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Primary Care POC Diagnostics Market Report Structure
3. Primary Care POC Diagnostics Market Trends And Strategies
4. Primary Care POC Diagnostics Market - Macro Economic Scenario
5. Primary Care POC Diagnostics Market Size And Growth
…..
27. Primary Care POC Diagnostics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.